Clinical Trials
21 trialsNCT06885424 2026-05-20
DESCENT-1
A2 Biotherapeutics Inc.
Enrolling by invitation
NCT05520099 2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
NCT06163534 2026-04-06
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Tempus AI
Recruiting
NCT05296135 2026-02-27
PREDAPT-HNSCC2
Cofactor Genomics, Inc.
Withdrawn
NCT04490564 2025-12-30
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Pharmassist Ltd
Completed
NCT07246759 2025-11-24
NEUTROFLOW
OncoHost Ltd.
Not yet recruiting
NCT06771674 2025-09-09
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Hookipa Biotech GmbH
Completed
NCT05059444 2025-08-22
ORACLE
Guardant Health, Inc.
Recruiting
NCT05451303 2025-01-29
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
Viome
Recruiting
NCT06174428 2025-01-29
Validity of Viome's Oral/throat Cancer Test
Viome
Recruiting
NCT04622462 2024-11-07
Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment
Proteocyte Diagnostics Inc.
Recruiting
NCT04825873 2023-10-13
A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China
Bristol-Myers Squibb
Completed
NCT05685524 2023-01-17
Clinical Study of Pan-cancer DNA Methylation Test in Plasma
Wuhan Ammunition Life-tech Co., Ltd
Unknown
NCT05068609 2022-05-05
VOLUME-PRO
Bristol-Myers Squibb
Completed
NCT05123950 2021-11-17
A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe
Bristol-Myers Squibb
Completed
NCT05049408 2021-09-28
Verification of Saliva MMP-1 as a Diagnostic Marker of Oral Cavity Cancer
S&T Biomed Co., Ltd.
Completed
NCT03253575 2019-04-08
ANCERS-2
Mitra RxDx, Inc.
Suspended
NCT01587573 2018-04-12
Developing an In-vitro Diagnostic Risk-Stratification Test for Oral Cancer
PeriRx
Unknown
NCT02543476 2017-11-14
SUPREME-HN
AstraZeneca
Completed
NCT02972216 2016-11-23
Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy
Yung Shin Pharm. Ind. Co., Ltd.
Completed
NCT01080066 2014-07-08
A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)
Merck KGaA, Darmstadt, Germany
Completed